Tarsin, W.Y., Pearson, S.B., Assi, K.H. and Chrystyn, Henry (2006) Emitted dose estimates from Seretide, Diskus and Symbicort Turbuhaler following inhalation by severe asthmatics. International Journal of Pharmaceutics, 316. pp. 131-137. ISSN 0378-5173
Restricted to Registered users only
The dose emitted from dry powder inhalers may be inhalation flow-dependent. Using an ex vivo method, the Electronic Lung™, we have measured the aerodynamic characteristics of the emitted dose for both active constituents from Seretide® Diskus® (salmeterol xinafoate 50 mcg; fluticasone propionate 500 mcg) and Symbicort® Turbuhaler® (formoterol 6 mcg; budesonide 200 mcg).1 Electronic inhalation profiles were collected from 20 severe asthmatics (mean PEFR 53% predicted) when they inhaled using a placebo Seretide® Diskus® and a placebo Symbicort® Turbuhaler®. These were replayed in the Electronic Lung™ with the respective active inhaler in situ. Mean(S.D.) peak inhalation flow rates (PIFR) through the Diskus® and Turbuhaler® were 94.7(32.9) and 76.8(26.2) l min−1, respectively. From the Electronic Lung™ the Diskus® inhalation profiles provided a mean(S.D.) fine particle dose (FPD) for fluticasone propionate and salmeterol of 20.4(4.8) and 18.4(4.4)% labelled dose. For Turbuhaler® inhalation profiles the FPD was 23.1(12.9) and 20.7(11.1)% labelled dose for budesonide and formoterol, respectively. The linear (p < 0.001) relationships between FPD against PIFR for budesonide and formoterol were 3 (p = 0.002) and 2.8 (p = 0.007) times steeper than fluticasone propionate and salmeterol, respectively. The results highlight a more significant effect of inspiratory flow on variable dosage emission when using the Symbicort® Turbuhaler® compared with the Seretide® Diskus®.
|Additional Information:||Copyright © 2006 Elsevier B.V. All rights reserved.|
|Uncontrolled Keywords:||Diskus®; Turbuhaler®; Asthma; Electronic Lung™; Dose|
|Subjects:||R Medicine > RS Pharmacy and materia medica|
|Schools:||School of Applied Sciences|
Ashurst et al., 1998 I.C. Ashurst, D. Prime and P.A. Haywood, Development of a dry powder inhaler device containing a combination of salmeterol and fluticasone propionate, Eur. Respir. J. 12 (1998), p. 93s.
Assi and Chrystyn, 2001 K.H. Assi and H. Chrystyn, The different resistance of dry powder inhalers (DPIs), Am. J. Respir. Crit. Care Med. 163 (2001), p. A443.
Bisgaard et al., 1998 H. Bisgaard, B. Klug, B.S. Sumby and P.K.P. Burnell, Fine particle mass from the Diskus inhaler and Turbuhaler inhaler in children with asthma, Eur. Respir. J. 11 (1998), pp. 1111–1115. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (60)
Bland and Altman, 1986 J.M. Bland and D.G. Altman, Statistical methods for assessing agreement between two methods of clinical measurement, Lancet 8 (1986), pp. 307–310. View Record in Scopus | Cited By in Scopus (11581)
Brindley et al., 1994 A. Brindley, B.S. Sumby and I.J. Smith, The characterisation of inhalation devices by an inhalation simulator; the Electronic Lung, J. Aerosol Med. 7 (1994), pp. 197–200. View Record in Scopus | Cited By in Scopus (1)
Broeders et al., 2001 M.E.A.C. Broeders, J. Molema, N.A. Vermue and H.T.M. Folgering, Peak inspiratory flow rate and slope of inhalation profiles in dry powder inhalers, Eur. Respir. J. 18 (2001), pp. 780–783. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (9)
Broeders et al., 2003 M.E.A.C. Broeders, J. Molema, N.A. Vermue and H.T.M. Folgering, In Check Dial: accuracy for Diskus and Turbuhaler, Int. J. Pharm. 252 (2003), pp. 275–280. SummaryPlus | Full Text + Links | PDF (94 K) | View Record in Scopus | Cited By in Scopus (8)
Burnell et al., 1998a P.K.P. Burnell, A. Malton, K. Reavill and M. Ball, Design, validation and initial testing of the Electronic Lung, J. Aerosol Sci. 29 (1998), pp. 1011–1025. Abstract | PDF (819 K) | View Record in Scopus | Cited By in Scopus (19)
Burnell et al., 1998b P.K.P. Burnell, A.C. Grant, P.A. Haywood, D. Prime and B. Sumby, Powder inhalers-exploring the limits of performance, Respir. Drug Deliv. VI (1998), pp. 259–266.
Burnell et al., 2001 P.K.P. Burnell, T. Small, S. Doig, B. Johal, R. Jenkins and G.J. Gibson, Ex vivo product performance of Diskus and Turbuhaler inhalers using inhalation profiles from patients with severe chronic obstructive pulmonary disease, Respir. Med. 95 (2001), pp. 324–330. Abstract | Abstract + References | PDF (408 K) | View Record in Scopus | Cited By in Scopus (17)
Chrystyn, 2003 H. Chrystyn, Is inhalation rate important for a dry powder inhaler? Using the In-Check Dial to identify these rates, Respir. Med. 97 (2003), pp. 181–187. Abstract | Abstract + References | PDF (309 K) | View Record in Scopus | Cited By in Scopus (12)
Clark and Hollingworth, 1993 A.R. Clark and A.M. Hollingworth, The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers—implications for in vitro testing, J. Aerosol Med. 6 (1993), pp. 99–110. View Record in Scopus | Cited By in Scopus (107)
Engel et al., 1989 T. Engel, J.H. Heinig, H.-J. Malling, B. Scharling, K. Nikander and F. Madesen, Clinical comparison of inhaled budesonide delivered either via pressurized metered dose inhaler or Turbuhaler®, Allergy 104 (1989), pp. 220–225. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (51)
Everard et al., 1997 M.L. Everard, S.G. Devadason and P.N. Le Soeuf, Flow early in the inspiratory manoeuvre affects the aerosol particle size distribution from a Turbuhaler, Respir. Med. 91 (1997), pp. 624–628. SummaryPlus | Full Text + Links | PDF (490 K) | View Record in Scopus | Cited By in Scopus (54)
Ganderton, 1997 D. Ganderton, General factors influencing drug delivery to the lung, Respir. Med. 91 (1997), pp. 13–16. SummaryPlus | Full Text + Links | PDF (387 K) | View Record in Scopus | Cited By in Scopus (34)
Ganderton and Kassem, 1992 D. Ganderton and N.M. Kassem, Dry powder inhalers, Adv. Pharm. Sci. (1992), pp. 165–191.
Martonen and Katz, 1993 B. Martonen and I.M. Katz, Deposition patterns of aerosolised drugs within human lungs. Effects of ventilatory parameters, Pharm. Res. 10 (1993), pp. 871–878.
Newman et al., 1991 S.P. Newman, F. Moren, E. Trofast, N. Talaee and S.W. Clarke, Terbutaline sulphate Turbuhaler: effect of inhaled flow rate on drug deposition and efficacy, Int. J. Pharm. 74 (1991), pp. 209–213. Abstract | Abstract + References | PDF (440 K) | View Record in Scopus | Cited By in Scopus (74)
Nielsen et al., 1997 K.G. Nielsen, M. Skov, B. Klug, M. Ifversen and H. Bisgaard, Flow-dependent effect of formoterol dry-powder inhaled from an Aerolizer, Eur. Respir. J. 10 (1997), pp. 210–2109.
Nunn and Gregg, 1989 A.J. Nunn and I. Gregg, New regression equation for predicting peak expiratory flow in adults, BMJ 298 (1989), pp. 1068–1070. View Record in Scopus | Cited By in Scopus (94)
Pauwels, 1997 R.A. Pauwels, Inhalation device, pulmonary deposition and clinical effects of inhaled therapy, J. Aerosol Med. 10 (1997), pp. S17–S21. View Record in Scopus | Cited By in Scopus (4)
Selroos et al., 1996 O. Selroos, A. Pietinhalho and H. Riska, Delivery devices for inhaled asthma medications; clinical implications of differences in effectiveness, Clin. Immunother. 6 (1996), pp. 273–279.
Tarsin et al., 2004 W. Tarsin, K.H. Assi and H. Chrystyn, In vitro intra- and inter-inhaler flow rate-dependent dosage emission from a combination of budesonide and eformoterol in a dry powder inhaler, J. Aerosol Med. 17 (2004), pp. 25–32. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (9)
USP, 2000 United States Pharmacopoeia, USP 24, NF 19, 2000. <601> Aerosols, Metered Dose Inhalers, and Dry Powder Inhalers, pp. 1895–1912.
|Depositing User:||Briony Heyhoe|
|Date Deposited:||09 Oct 2007|
|Last Modified:||01 Dec 2016 14:22|
Downloads per month over past year
Repository Staff Only: item control page